Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were the 3 most prominent ADCs in EGFR-amplified glioblastoma.
Sonia Jain, PhD
Advertisement
Articles by Sonia Jain, PhD
Advertisement
Latest Updated Articles
What Is the Current State of ADC Treatment in EGFR-Amplified Glioblastoma?Published: November 17th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Interpreting Overall Survival and Subgroup Outcomes in MATTERHORN: Where DFLOT Shows Strength and Where Questions Remain
2
Bioimpedance Spectroscopy is Allowing for Lymphedema Reduction in Breast Cancer
3
Janjigian Provides Perspective on Durvalumab Combo Approval in Gastric/GEJ Cancer
4
What’s New in Hematology/Oncology? Discussing the 2025 ASH Annual Meeting
5